Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Recruiting
18 years or above
All
Phase N/A
110 participants needed
1 Location

Study Overview

This is a multi-center, hospital based, cross-sectional study based on data from patient medical records, including laboratory results. The study will include adult patients with chronic (> 1 year duration) primary Immune Thrombocytopenia (ITP) only. Patients will be identified based on a laboratory confirmed diagnosis of ITP in the medical records, where there is also a physician-confirmed diagnosis of primary ITP. If patients consent to take part in the study, a routine clinical visit will also serve as the study visit.

All study participants will have a routine blood test as part of their standard clinical care at the study visit, and this same procedure will be used to collect supplementary blood samples to assess a variety of biomarkers.

Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia, Adult Immune Thrombocytopenia
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • Patient diagnosed with chronic (ITP with > 1 year duration) primary ITP living in the USA or the UK:
  • On ITP pharmacologic treatment, regardless of last platelet count (below or above 100 x 10^9 counts/L);
  • Patients in remission as per their most recent blood test (platelet count >100 x 10^9 counts/L) and without ITP-specific treatment for less than 1 year
  • Adult patient who are 18 years or older at index date
  • Patient who has received at least one initial first line therapy (corticosteroids [CS]/ intravenous immunoglobulin [IVIg]/ANTI d) with initial response (platelet count ≥ 50 x 10^9 counts/L) as of index date

Exclusion Criteria:

  • Secondary ITP
  • Patients in remission as per their most recent blood test (platelet count >100 x 10^9 counts/L) and without ITP-specific treatment for 1 year or more
  • Patients with recent or active infection recorded 14 days or less before index date; patients with uncontrolled chronic infections or who were recently diagnosed with a chronic infection (≤14 days of index date).
  • Patients with vaccination in 28 days before index date
  • Patients treated with rilzabrutinib on or before index date

Updated on 02 Apr 2025. Study ID: NCT06665308

Find a Study Location to Connect

Your contact details have been shared with the study team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language